Hiroko Ohgaki

List of Publications by Year
in descending order

141 papers	41,492 citations	13827 67 h-index	12558 132 g-index
143 all docs	143 docs citations	143 times ranked	32831 citing authors

#	Article	IF	Citations
1	CASP9 germline mutation in a family with multiple brain tumors. Brain Pathology, 2018, 28, 94-102.	2.1	11
2	Germline MSH6 Mutation in a Patient With Two Independent Primary Glioblastomas. Journal of Neuropathology and Experimental Neurology, 2017, 76, 848-853.	0.9	4
3	Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer, 2016, 122, 2206-2215.	2.0	77
4	Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. Brain Pathology, 2016, 26, 517-522.	2.1	63
5	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 2016, 131, 803-820.	3.9	12,144
6	Braf Mutations Initiate the Development of Rat Gliomas Induced by Postnatal Exposure to N-Ethyl-N-Nitrosourea. American Journal of Pathology, 2016, 186, 2569-2576.	1.9	7
7	Epidemiology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 3-18.	1.0	15
8	Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas. Journal of Neuropathology and Experimental Neurology, 2015, 74, 952-959.	0.9	52
9	Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas. Journal of Neuro-Oncology, 2014, 120, 283-291.	1.4	7
10	Alterations of theRRASandERCC1Genes at 19q13 in Gemistocytic Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2014, 73, 908-915.	0.9	7
11	TP53, MSH4, and LATS1 Germline Mutations in a Family with Clustering of Nervous System Tumors. American Journal of Pathology, 2014, 184, 2374-2381.	1.9	22
12	<scp>I</scp>nternational <scp>S</scp>ociety of <scp>N</scp>europathologyâ€<scp>H</scp>aarlem <scp>C</scp>onsensus <scp>G</scp>uidelines for <scp>N</scp>ervous <scp>S</scp>ystem <scp>T</scp>umor <scp>C</scp>lassification and <scp>G</scp>rading. Brain Pathology, 2014, 24, 429-435.	2.1	499
13	Definition of Primary and Secondary Glioblastomaâ€”Response. Clinical Cancer Research, 2014, 20, 2013-2013.	3.2	29
14	Contribution of Molecular Biology to the Classification of Low-Grade Diffuse Glioma. , 2013, , 61-72.		0
15	TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathologica, 2013, 126, 931-937.	3.9	209
16	The Definition of Primary and Secondary Glioblastoma. Clinical Cancer Research, 2013, 19, 764-772.	3.2	819
17	<scp>MET</scp> Gain in Diffuse Astrocytomas is Associated with Poorer Outcome. Brain Pathology, 2013, 23, 13-18.	2.1	37
18	PDGFRAGain in Low-Grade Diffuse Gliomas. Journal of Neuropathology and Experimental Neurology, 2013, 72, 61-66.	0.9	13

#	Article	IF	Citations
19	DMBT1Homozygous Deletion in Diffuse Astrocytomas Is Associated With Unfavorable Clinical Outcome. Journal of Neuropathology and Experimental Neurology, 2012, 71, 702-707.	0.9	15
20	Transcriptional Factors for Epithelialâ€“Mesenchymal Transition Are Associated with Mesenchymal Differentiation in Gliosarcoma. Brain Pathology, 2012, 22, 670-676.	2.1	45
21	Amplification of the STOML3, FREM2, and LHFP Genes Is Associated with Mesenchymal Differentiation in Gliosarcoma. American Journal of Pathology, 2012, 180, 1816-1823.	1.9	28
22	Frequent BRAF Gain in Lowâ€Grade Diffuse Gliomas with 1p/19q Loss. Brain Pathology, 2012, 22, 834-840.	2.1	34
23	KIAA1549â€BRAF Fusions and IDH Mutations Can Coexist in Diffuse Gliomas of Adults. Brain Pathology, 2012, 22, 841-847.	2.1	55
24	Genetic Alterations in MicroRNAs in Medulloblastomas. Brain Pathology, 2012, 22, 230-239.	2.1	48
25	MicroRNA-21 suppression impedes medulloblastoma cell migration. European Journal of Cancer, 2011, 47, 2479-2490.	1.3	63
26	Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study. Neuropathology, 2011, 31, 583-588.	0.7	36
27	Alterations in the RB1 Pathway in Lowâ€grade Diffuse Gliomas Lacking Common Genetic Alterations. Brain Pathology, 2011, 21, 645-651.	2.1	29
28	Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathology, 2011, 28, 177-183.	1.1	146
29	Molecular signatures classify astrocytic gliomas by IDH1 mutation status. International Journal of Cancer, 2011, 128, 1095-1103.	2.3	75
30	TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations: Figure 1. Journal of Clinical Pathology, 2011, 64, 850-852.	1.0	65
31	Nervous system tumors associated with familial tumor syndromes. Current Opinion in Neurology, 2010, 23, 583-591.	1.8	21
32	Intratumoral Patterns of Genomic Imbalance in Glioblastomas. Brain Pathology, 2010, 20, 936-944.	2.1	67
33	Molecular Classification of Low-Grade Diffuse Gliomas. American Journal of Pathology, 2010, 177, 2708-2714.	1.9	218
34	IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas. Clinical Cancer Research, 2009, 15, 6002-6007.	3.2	604
35	Promoter Methylation and Polymorphisms of the MGMT Gene in Glioblastomas: A Population-Based Study. Neuroepidemiology, 2009, 32, 21-29.	1.1	87
36	Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas. BMC Cancer, 2009, 9, 268.	1.1	24

#	Article	IF	Citations
37	Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathologica, 2009, 117, 653-656.	3.9	71
38	Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Science, 2009, 100, 2235-2241.	1.7	374
39	Common Polymorphisms in the MDM2 and TP53 Genes and the Relationship between TP53 Mutations and Patient Outcomes in Glioblastomas. Brain Pathology, 2009, 19, 188-194.	2.1	37
40	Whole Genome Amplification for Array Comparative Genomic Hybridization Using DNA Extracted from Formalin-Fixed, Paraffin-Embedded Histological Sections. Journal of Molecular Diagnostics, 2009, 11, 109-116.	1.2	17
41	Epidemiology of Brain Tumors. Methods in Molecular Biology, 2009, 472, 323-342.	0.4	320
42	Age as a Predictive Factor in Glioblastomas: Population-Based Study. Neuroepidemiology, 2009, 33, 17-22.	1.1	108
43	IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas. American Journal of Pathology, 2009, 174, 1149-1153.	1.9	877
44	Mutational Inactivation of the Nijmegen Breakage Syndrome Gene (NBS1) in Glioblastomas Is Associated With Multiple TP53 Mutations. Journal of Neuropathology and Experimental Neurology, 2009, 68, 210-215.	0.9	14
45	Immunohistochemical and ultrastructural characterization of brain tumors in S100Î²-v-erbB transgenic rats. Neuropathology, 2008, 28, 080521172700523-???.	0.7	8
46	Mutations in the Nijmegen Breakage Syndrome Gene in Medulloblastomas. Clinical Cancer Research, 2008, 14, 4053-4058.	3.2	26
47	Genetic Pathways to Primary and Secondary Glioblastoma. American Journal of Pathology, 2007, 170, 1445-1453.	1.9	1,250
48	Congenital Glioblastoma: A Clinicopathologic and Genetic Analysis. Brain Pathology, 2007, 17, 276-281.	2.1	51
49	PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathologica, 2007, 113, 295-302.	3.9	90
50	The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica, 2007, 114, 97-109.	3.9	9,898
51	Brain Tumors in S100Î²-v-erbB Transgenic Rats. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1111-1117.	0.9	13
52	Correlation Among Pathology, Genotype, and Patient Outcomes in Glioblastoma. Journal of Neuropathology and Experimental Neurology, 2006, 65, 846-854.	0.9	157
53	Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathologica, 2006, 112, 5-12.	3.9	87
54	Altered Expression of Immune Defense Genes in Pilocytic Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2005, 64, 891-901.	0.9	51

#	Article	IF	Citations
55	Genetic pathways to glioblastomas. Neuropathology, 2005, 25, 1-7.	0.7	194
56	Epidemiology and etiology of gliomas. Acta Neuropathologica, 2005, 109, 93-108.	3.9	1,041
57	TP53 promoter methylation in human gliomas. Acta Neuropathologica, 2005, 110, 178-184.	3.9	87
58	Population-Based Studies on Incidence, Survival Rates, and Genetic Alterations in Astrocytic and Oligodendroglial Gliomas. Journal of Neuropathology and Experimental Neurology, 2005, 64, 479-489.	0.9	1,174
59	Genetic Pathways in the Evolution of Gliomas. , 2005, , 207-221.		0
60	Genetic Pathways to Glioblastoma. Cancer Research, 2004, 64, 6892-6899.	0.4	1,137
61	Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene, 2004, 23, 6012-6022.	2.6	56
62	Predominant Expression of Mutant EGFR (EGFRvIII) is Rare in Primary Glioblastomas. Brain Pathology, 2004, 14, 131-136.	2.1	118
63	Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathologica, 2004, 108, 49-56.	3.9	288
64	Molecular pathogenesis of astrocytic tumours. Journal of Neuro-Oncology, 2004, 70, 137-160.	1.4	114
65	APC mutations are infrequent but present in human lung cancer. Cancer Letters, 2004, 207, 197-203.	3.2	77
66	Genetic and Expression Profiles of Cerebellar Liponeurocytomas. Brain Pathology, 2004, 14, 281-289.	2.1	69
67	PTEN methylation and expression in glioblastomas. Acta Neuropathologica, 2003, 106, 479-485.	3.9	113
68	Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. International Journal of Cancer, 2003, 106, 334-341.	2.3	207
69	AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene, 2003, 22, 632-636.	2.6	140
70	Null Mutation of DNA Strand Break-Binding Molecule Poly(ADP-ribose) Polymerase Causes Medulloblastomas in p53â˜†/â˜† Mice. American Journal of Pathology, 2003, 162, 343-352.	1.9	146
71	Î²-Catenin mutations in liver tumors induced by 2-amino-3,4-dimethylimidazo[4,5-f]quinoline in CDF1 mice. Cancer Letters, 2003, 198, 29-35.	3.2	15
72	A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. Journal of Neurosurgery, 2003, 98, 1170-1174.	0.9	215

#	Article	IF	Citations
73	Genetic basis of glioma progression. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2003, 79B, 78-85.	1.6	1
74	Granular Cell Astrocytomas Show a High Frequency of Allelic Loss but are not a Genetically Defined Subset. Brain Pathology, 2003, 13, 185-194.	2.1	30
75	Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Research, 2003, 63, 6643-50.	0.4	350
76	Methylation of the p73 gene in gliomas. Acta Neuropathologica, 2002, 104, 357-362.	3.9	43
77	Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathologica, 2002, 103, 267-275.	3.9	126
78	Second Primary Glioblastoma. Journal of Neuropathology and Experimental Neurology, 2001, 60, 208-215.	0.9	16
79	Promoter hypermethylation and homozygous deletion of the p14 ARF and p16 INK4a genes in oligodendrogliomas. Acta Neuropathologica, 2001, 101, 185-189.	3.9	79
80	Aspects of intracranial and spinal tumors in patients with Down syndrome and report of a rapidly progressing Grade 2 astrocytoma. Cancer, 2001, 91, 1458-1466.	2.0	21
81	Reduced expression of the A? subunit of protein phosphatase 2A in human gliomas in the absence of mutations in the A? and A? subunit genes. International Journal of Cancer, 2001, 93, 798-804.	2.3	60
82	Invasiveness in vitro and biological markers in human primary glioblastomas. Journal of Neuro-Oncology, 2001, 54, 1-8.	1.4	16
83	Mutation analysis of hBUB1, hBUBR1 and hBUB3 genes in glioblastomas. Acta Neuropathologica, 2001, 101, 297-304.	3.9	29
84	Genetic evidence of the neoplastic nature of gemistocytes in astrocytomas. Acta Neuropathologica, 2001, 102, 422-425.	3.9	30
85	Promoter Hypermethylation of the RB1 Gene in Glioblastomas. Laboratory Investigation, 2001, 81, 77-82.	1.7	158
86	Germline SDHD mutation in paraganglioma of the spinal cord. Oncogene, 2001, 20, 5084-5086.	2.6	40
87	Concurrent Inactivation of RB1 and TP53 Pathways in Anaplastic Oligodendrogliomas. Journal of Neuropathology and Experimental Neurology, 2001, 60, 1181-1189.	0.9	92
88	p14^{ARF} Deletion and Methylation in Genetic Pathways to Glioblastomas. Brain Pathology, 2001, 11, 159-168.	2.1	197
89	Aspects of intracranial and spinal tumors in patients with Down syndrome and report of a rapidly progressing Grade 2 astrocytoma. , 2001, 91, 1458.		1
90	Loss of Heterozygosity on Chromosome 19 in Secondary Glioblastomas. Journal of Neuropathology and Experimental Neurology, 2000, 59, 539-543.	0.9	118

#	Article	IF	Citations
91	Effect of Intragastric Application ofN-Methylnitrosourea inp53 Knockout Mice. Molecular Carcinogenesis, 2000, 28, 97-101.	1.3	17
92	Loss of Heterozygosity on Chromosome 10 Is More Extensive in Primary (De Novo) Than in Secondary Glioblastomas. Laboratory Investigation, 2000, 80, 65-72.	1.7	145
93	Phenotype vs Genotype in the Evolution of Astrocytic Brain Tumors. Toxicologic Pathology, 2000, 28, 164-170.	0.9	96
94	More About: Cell and Molecular Biology of Simian Virus 40: Implications for Human Infections and Disease. Journal of the National Cancer Institute, 2000, 92, 495-496.	3.0	30
95	p53 knockout mice (-/-) are more susceptible than (+/-) or (+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis. Carcinogenesis, 2000, 21, 1891-1897.	1.3	58
96	Genetic Profile of Gliosarcomas. American Journal of Pathology, 2000, 156, 425-432.	1.9	212
97	APC Mutations in Sporadic Medulloblastomas. American Journal of Pathology, 2000, 156, 433-437.	1.9	247
98	Human astrocytic brain tumors express APO2L/TRAIL. Acta Neuropathologica, 1999, 97, 1-4.	3.9	52
99	A case history of glioma progression. Acta Neuropathologica, 1999, 97, 525-532.	3.9	27
100	Molecular analysis of glioma and skin-tumour alterations in a xeroderma-pigmentosum child. , 1999, 81, 345-350.		14
101	Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro-Oncology, 1999, 1, 44-51.	0.6	456
102	Acquisition of the Glioblastoma Phenotype during Astrocytoma Progression Is Associated with Loss of Heterozygosity on 10q25-qter. American Journal of Pathology, 1999, 155, 387-394.	1.9	120
103	Î²-Catenin Mutations Are Frequent in Human Hepatocellular Carcinomas Associated with Hepatitis C Virus Infection. American Journal of Pathology, 1999, 155, 1795-1801.	1.9	261
104	Identification in Human Brain Tumors of DNA Sequences Specific for SV40 Large T Antigen. Brain Pathology, 1999, 9, 33-42.	2.1	94
105	p53 mutations in sweat gland carcinomas. , 1998, 76, 317-320.		36
106	Carcinomas of the renal pelvis associated with smoking and phenacetin abuse:p53 mutations and polymorphism of carcinogen-metabolising enzymes. , 1998, 79, 531-536.		27
107	Necrogenesis and Fas/APO-1 (CD95) Expression in Primary (de novo) and Secondary Glioblastomas. Journal of Neuropathology and Experimental Neurology, 1998, 57, 239-245.	0.9	62
108	PTEN (MMAC1) Mutations Are Frequent in Primary Glioblastomas (de novo) but not in Secondary Glioblastomas. Journal of Neuropathology and Experimental Neurology, 1998, 57, 684-689.	0.9	209

#	Article	IF	Citations
109	Astrocytomas and Choroid Plexus Tumors in Two Families with Identical p53 Germline Mutations. Journal of Neuropathology and Experimental Neurology, 1998, 57, 1061-1069.	0.9	47
110	CD95 Ligand: Lethal Weapon Against Malignant Glioma?. Brain Pathology, 1998, 8, 285-293.	2.1	69
111	Amplification and Overexpression of MDM2 in Primary (de novo) Glioblastomas. Journal of Neuropathology and Experimental Neurology, 1997, 56, 180-185.	0.9	144
112	p53 Mutations versus EGF Receptor Expression in Giant Cell Glioblastomas. Journal of Neuropathology and Experimental Neurology, 1997, 56, 1236-1241.	0.9	53
113	Fas Ligand Expression in Glioblastoma Cell Lines and Primary Astrocytic Brain Tumors. Brain Pathology, 1997, 7, 863-869.	2.1	142
114	Genetics of Glioma Progression and the Definition of Primary and Secondary Glioblastoma. Brain Pathology, 1997, 7, 1131-1136.	2.1	69
115	Overexpression of the EGF Receptor and p53 Mutations are Mutually Exclusive in the Evolution of Primary and Secondary Glioblastomas. Brain Pathology, 1996, 6, 217-223.	2.1	664
116	Infrequent alterations of thep15, p16, CDK4 andCYCLIN D1 genes in non-astrocytic human brain tumors. , 1996, 66, 305-308.		67
117	Immunohistochemical Assessments of P53 Protein Accumulation and Tumor Growth Fraction During the Progression of Astrocytomas. , 1996, , 255-262.		4
118	Genetic and environmental factors in the etiology of human brain tumors. Toxicology Letters, 1995, 82-83, 601-605.	0.4	19
119	p53 mutations in primary human lung tumors and their metastases. Molecular Carcinogenesis, 1994, 9, 105-109.	1.3	72
120	p53 gene mutations in oropharyngeal carcinomas: A comparison of solitary and multiple primary tumours and lymph-node metastases. International Journal of Cancer, 1994, 56, 807-811.	2.3	56
121	p53 protein accumulation and gene mutations in human glioma cell lines. International Journal of Cancer, 1993, 55, 982-987.	2.3	66
122	Mutations of thep53 tumor suppressor gene in neoplasms of the human nervous system. Molecular Carcinogenesis, 1993, 8, 74-80.	1.3	205
123	Comparative Study of p53 Gene and Protein Alterations in Human Astrocytic Tumors. Journal of Neuropathology and Experimental Neurology, 1993, 52, 31-38.	0.9	203
124	Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children. Association with an activated K-ras gene. Cancer, 1992, 69, 2385-2392.	2.0	77
125	Carcinogenicities of heterocyclic amines in cooked food. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1991, 259, 399-410.	1.2	286
126	Ki-ras mutations in spontaneous and chemically induced renal tumors of the rat. Molecular Carcinogenesis, 1991, 4, 455-459.	1.3	15

#	Article	IF	Citations
127	Induction of tumors in the Zymbal gland, oral cavity, colon, skin and mammary gland of F344 rats by a	1.3	68
128	Induction of Lymphoma in CDF1Mice by the Food Mutagen, 2-Amino-l-methyl-6-phenylimidazo[4,5-b]pyridine. Japanese Journal of Cancer Research, 1989, 80, 1176-1178.	1.7	208
129	Carcinogenicity in rats of a mutagenic compound, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline. Carcinogenesis, 1988, 9, 71-73.	1.3	156
130	Carcinogenicity in mice of a mutagenic compound, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) from cooked foods. Carcinogenesis, 1987, 8, 665-668.	1.3	161
131	Active H-ras and N-ras in rat fibrosarcomas induced by 1,6-dinitropyrene. Cancer Letters, 1987, 34, 317-324.	3.2	11
132	Induction of hepatocellular carcinoma and highly metastatic squamous cell carcinomas in the forestomach of mice by feeding 2-amino-3, 4-dimethylimidazo[4, 5-f]quinoline. Carcinogenesis, 1986, 7, 1889-1893.	1.3	55
133	Induction of tumors in the forestomach and liver of mice by feeding 2-amino-3,4-dimethylimidazo(4,5-f)quinoline (MeIQ).. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 1985, 61, 137-139.	1.6	16
134	Absence of carcinogenicity of 1-nitropyrene, correction of previous results, and new demonstration of carcinogenicity of 1,6-dinitropyrene in rats. Cancer Letters, 1985, 25, 239-245.	3.2	67
135	Atrophy of salivary glands and pancreas of rats fed on diet with amino-methyl-.ALPHA.-carboline.. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 1985, 61, 277-280.	1.6	21
136	Activation of K-ras and oncogenes other than ras family in rat fibrosarcomas induced by 1,8-dinitropyrene. Cancer Letters, 1985, 29, 119-125.	3.2	24
137	Induction of sarcomas in rats by subcutaneous injection of dinitropyrenes. Carcinogenesis, 1984, 5, 583-585.	1.3	93
138	Carcinogenicity in mice of mutagenic compounds from glutamic acid and soybean globulin pyrolysates. Carcinogenesis, 1984, 5, 815-819.	1.3	99
139	Carcinogenicity in mice of a mutagenic compound, 2-amino-3-methylimidazo[4,5-f]quinoline, from broiled sardine, cooked beef and beef extract. Carcinogenesis, 1984, 5, 921-924.	1.3	194
140	Carcinogenicity in rats of the mutagenic compounds 1-nitropyrene and 3-nitrofluoranthene. Cancer Letters, 1982, 15, 1-7.	3.2	175
141	Aspects of intracranial and spinal tumors in patients with Down syndrome and report of a rapidly progressing Grade 2 astrocytoma. , 0, .		1